StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Outlook Therapeutics's operating margin for the twelve months ending Sep 30, 2019 was -445.6%. For fiscal 2025 it was -4744.3%, against -445.6% the year before. The highest annual figure on record is -445.6% in fiscal 2019.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Sep 30, 2025-4744.3%−4298.7
FY2019Sep 30, 2019-445.6%+514.5
FY2018Sep 30, 2018-960.1%−18.8
FY2017Sep 30, 2017-941.4%+781.9
FY2016Sep 30, 2016-1723.3%−831.2
FY2015Sep 30, 2015-892.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q3 FY2025CQ2 2025Jun 30, 2025-1046.2%−85.4
Q4 FY2019CQ3 2019Sep 30, 2019-216.8%+1391.4
Q3 FY2019CQ2 2019Jun 30, 2019-966.7%−31.4
Q2 FY2019CQ1 2019Mar 31, 2019-1201.9%−316.9
Q1 FY2019CQ4 2018Dec 31, 2018-960.8%−548.8
Q4 FY2018CQ3 2018Sep 30, 2018-1608.2%−1507.9
Q3 FY2018CQ2 2018Jun 30, 2018-935.4%+1484.8
Q2 FY2018CQ1 2018Mar 31, 2018-885.0%+1700.6
Q1 FY2018CQ4 2017Dec 31, 2017-411.9%+5458.4
Q4 FY2017CQ3 2017Sep 30, 2017-100.3%+1910.7
Q3 FY2017CQ2 2017Jun 30, 2017-2420.1%+2030.8
Q2 FY2017CQ1 2017Mar 31, 2017-2585.6%−2288.7
Q1 FY2017CQ4 2016Dec 31, 2016-5870.3%–
Q4 FY2016CQ3 2016Sep 30, 2016-2011.0%–
Q3 FY2016CQ2 2016Jun 30, 2016-4451.0%–
Q2 FY2016CQ1 2016Mar 31, 2016-296.9%–

More Outlook Therapeutics figures

See a number that looks wrong?